Clinical Trial Update: Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Bictegravir + Emtricitabine/Tenofovir Alafenamide to Dolutegravir + Emtricitabine/Tenofovir Alafenamide in antiretroviral treatment-naiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)
• Dolutegravir + Emtricitabine/Tenofovir Alafenamide (dolutegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-03-27